142818-01-7

Basic information

• Product Name: 1-phenyl-3-(trifluoromethyl)pyrazole-4-carboxylic acid
• Synonyms: 1-phenyl-3-(trifluoromethyl)pyrazole-4-carboxylic acid;1H-Pyrazole-4-carboxylic acid, 1-phenyl-3-(trifluoromethyl)-;3-(trifluoroMethyl)-1-phenyl-1H-pyrazol-4-carboxylic acid;1-Phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid
• CAS NO: 142818-01-7
• Molecular Formula: C₁₁H₇F₃N₂O₂
• Molecular Weight: 256.19
• Mol File: 142818-01-7.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-phenyl-3-(trifluoromethyl)pyrazole-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-phenyl-3-(trifluoromethyl)pyrazole-4-carboxylic acid(142818-01-7)
• EPA Substance Registry System: 1-phenyl-3-(trifluoromethyl)pyrazole-4-carboxylic acid(142818-01-7)

Safety Data

• Statements: 20/21/22
• Safety Statements: 36/37
• Hazardous Substances Data: 142818-01-7(Hazardous Substances Data)

Usage

Chemical Properties

White solid

Upstream product

• 142809-82-3 4-trifluoroacetyl-3-trifluoromethyl-1-phenylpyrazole 
• 142818-05-1 benzaldehyde N-<β,β-bis(trifluoroacetyl)vinyl>phenylhydrazone 
• 142503-29-5 3-dimethylaminomethylene-1,1,1,5,5,5-hexafluoropentane-2,4-dione 
• 142503-30-8 4-Ethylthio-1,1,1-trifluoro-3-(trifluoroacetyl)-3-buten-2-one 
• 100-63-0 phenylhydrazine 
• 588-64-7 benzaldehyde phenylhydrazone 
• 98-80-6 phenylboronic acid 
• 155377-19-8 ethyl 3-trifluoromethyl-1H-pyrazole-4-carboxylate 
• 741717-63-5 ethyl 1-phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate 
• 905590-60-5 N-(5-benzyl-4-phenyl-1,3-thiazol-2-yl)-4-phenyl-4-oxobutanamide 
• 571-55-1 ethyl 2-(ethoxymethylidene)-4,4,4-trifluoro-3-oxobutanoate 
• 155377-19-8 ethyl 5-(trifluoromethyl)-1H-pyrazole-4-carboxylate 
• 591-50-4 iodobenzene 

Downstream Products

• 1003579-30-3 (S)-methyl 3-[(tert-butoxycarbonyl)amino]-N-{[1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]carbonyl}alaninate 
• 1227166-15-5 tert-butyl [2-({[1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]carbonyl}amino)ethyl]carbamate 
• 1003578-15-1 (R)-methyl N-[(benzyloxy)carbonyl]-3-({[1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]carbonyl}amino)alaninate 
• 1003577-93-2 tert-butyl [2-({[1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]carbonyl}amino)propyl]carbamate 
• 1421917-34-1 N-(pyridin-4-yl)-1-phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide 
• 1421917-35-2 N-(2-chloropyridin-4-yl)-1-phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide 
• 1421917-36-3 N-(2-bromopyridin-4-yl)-1-phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide 
• 1421917-37-4 N-(pyridin-2-yl)-1-phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide 
• 1421917-38-5 N-(3-chloropyridin-4-yl)-1-phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide 
• 1421917-39-6 N-(3-bromopyridin-4-yl)-1-phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide 
• 1421917-40-9 N-(3-methylpyridin-4-yl)-1-phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide 
• 1421917-41-0 N-(2-methylpyridin-4-yl)-1-phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide 
• 1421917-42-1 N-(pyridin-3-yl)-1-phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide 
• 1421917-43-2 N-(5-chloropyridin-2-yl)-1-phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide 

Relevant articles and documents

Design and synthesis of close analogs of LCRF-0004, a potent and selective RON receptor tyrosine kinase inhibitor

Abstract New carboxamide head group analogs of thieno[3,2-b]pyridine-based kinase inhibitor LCRF-0004 were designed and synthesized. Potent and selective inhibitors of RON enzyme versus c-Met RTK were obtained.

Inhibitors of Diacylglycerol Acyltransferase

Provided herein are amides containing at least a four ring structure, which are inhibitors of diacylglycerol acyltransferase and are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS

Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.